MEMORIAL SLOAN-KETTERING CANCER CENTER
Patent Owner
Stats
- 126 US PATENTS IN FORCE
- 45 US APPLICATIONS PENDING
- Mar 20, 2018 most recent publication
Details
- 126 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 4,755 Total Citation Count
- Sep 01, 1982 Earliest Filing
- 109 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2018/0021,259 DYE-STABILIZED NANOPARTICLES AND METHODS OF THEIR MANUFACTURE AND THERAPEUTIC USEFeb 09, 16Jan 25, 18[A61K]
2018/0021,265 COMPOSITIONS AND METHODS FOR NANOPARTICLE-BASED DRUG DELIVERY AND IMAGINGFeb 17, 16Jan 25, 18[A61K]
2018/0008,709 METHODS AND COMPOSITIONS FOR INCREASING SUSCEPTIBILITY TO RADIATION TREATMENT BY INHIBITING SUPPRESSION OF NUMERICAL CHROMOSOMAL INSTABILITY OF CANCER CELLSJan 21, 16Jan 11, 18[A61K, A61N]
2017/0363,618 AGE-MODIFIED CELLS AND METHODS FOR MAKING AGE-MODIFIED CELLSJul 13, 17Dec 21, 17[C12Q, C12N, G01N]
2017/0363,635 Methods of Treating and Prognosing Nonhematopoietic Malignant TumorsDec 04, 15Dec 21, 17[A61K, C12Q, G01N]
2017/0348,234 METHOD AND COMPOSITION FOR TARGETED DELIVERY OF THERAPEUTIC AGENTSJul 23, 15Dec 07, 17[A61K, C12N]
2017/0334,966 ANTI-TUMOR ANTIBODY-TUMOR SUPPRESSOR FUSION PROTEIN COMPOSITIONS AND METHODS OF USE FOR THE TREATMENT OF CANCERAug 01, 17Nov 23, 17[A61K, G01N, C07K]
2017/0304,470 HSP90-TARGETED INFLAMMATION AND INFECTION IMAGING AND THERAPYSep 17, 15Oct 26, 17[A61K, A61B]
2017/0266,328 METAL(LOID) CHALCOGEN NANOPARTICLES AS UNIVERSAL BINDERS FOR MEDICAL ISOTOPESJul 28, 15Sep 21, 17[A61K]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2018/0015,184 METHOD AND COMPOSITION TO INCREASE RADIATION-INDUCED TUMOR THERAPEUTIC EFFECTSAbandonedJul 12, 16Jan 18, 18[A61K]
2016/0375,060 Methods of Treating Glioblastoma Multiforme by T Cell TherapyAbandonedJun 24, 16Dec 29, 16[A61K, C12N]
2016/0331,750 METHODS FOR TREATMENT OF LYMPHOMAS WITH MUTATIONS IN CELL CYCLE GENESAbandonedJan 07, 16Nov 17, 16[A61K, C12Q, G01N]
2016/0251,722 BRCA2-SPECIFIC MODIFIER LOCUS RELATED TO BREAST CANCER RISKAbandonedSep 25, 15Sep 01, 16[C12Q]
2016/0222,131 ATRX AS A COMPANION DIAGNOSTIC FOR CDK4 INHIBITORSAbandonedApr 21, 16Aug 04, 16[A61K, C12N, G01N, C07K]
2016/0152,725 ANTIGEN-BINDING PROTEINS SPECIFIC FOR HLA-A2-RESTRICTED WILMS TUMOR 1 PEPTIDEAbandonedFeb 25, 15Jun 02, 16[A61K, C07K]
2016/0138,113 METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF BRAIN METASTASISAbandonedJun 19, 14May 19, 16[C12Q]
2016/0138,115 METHODS AND CHARACTERISTICS FOR THE DIAGNOSIS OF ACUTE LYMPHOBLASTIC LEUKEMIAAbandonedJun 20, 14May 19, 16[C12Q, G01N, C07K]
2016/0117,440 SYSTEM AND METHOD FOR AUTOMATED PREDICTION OF VULNERABILITIES IN BIOLOGICAL SAMPLESAbandonedMay 29, 14Apr 28, 16[G06F]
2016/0015,760 NEWCASTLE DISEASE VIRUSES AND USES THEREOFAbandonedMar 04, 14Jan 21, 16[A61K, C12N, C07K]
2015/0359,913 TETRAZINES/TRANS-CYCLOOCTENES IN SOLID PHASE SYNTHESIS OF LABELED PEPTIDESAbandonedJan 24, 14Dec 17, 15[A61K]
2015/0343,100 BIMODAL FLUOROPHORE-LABELED LIPOSOMES AND ASSOCIATED METHODS AND SYSTEMSAbandonedMay 27, 15Dec 03, 15[A61K]
2015/0344,957 MONITORING TREATMENT OF HISTIOCYTOSIS WITH VEMURAFENIB AND DABRAFENIBAbandonedMay 30, 15Dec 03, 15[A61K, C12Q]
2015/0184,247 GENE EXPRESSION PROFILES ASSOCIATED WITH METASTATIC BREAST CANCERAbandonedApr 22, 13Jul 02, 15[C12Q]
2015/0185,224 PREDICTING BLADDER CANCER RESPONSIVENESS TO BCGAbandonedAug 07, 13Jul 02, 15[C12Q, G01N]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.